Spectrum Pharmaceuticals Announces the Completion of the Sale of its Marketed Portfolio
The completion of this sale marks a significant pivot point in Spectrums history as we focus our efforts on our two promising late stage assets, ROLONTIS and poziotinib, stated Joe Turgeon, President and CEO of Spectrum Pharmaceuticals.
- The completion of this sale marks a significant pivot point in Spectrums history as we focus our efforts on our two promising late stage assets, ROLONTIS and poziotinib, stated Joe Turgeon, President and CEO of Spectrum Pharmaceuticals.
- Spectrum has also reduced its staff by approximately 40 percent with the majority of impacted staff transitioning to Acrotech.
- SPECTRUM PHARMACEUTICALS, INC. , FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ, EVOMELA, and ROLONTIS are registered trademarks of Spectrum Pharmaceuticals, Inc. and its affiliates.
- KHAPZORYTM, REDEFINING CANCER CARE and the Spectrum Pharmaceuticals' logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.